{"filing":{"accession_number":"0001193125-26-285426","cik":"0001799448","ticker":"ALGS","company_name":"Aligos Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-26","report_date":null,"primary_document":"d70452d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1799448/000119312526285426/d70452d8k.htm"},"events":[{"id":14202,"run_id":12633,"accession_number":"0001193125-26-285426","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Stockholders voted at the Annual Meeting on five proposals: election of two Class III directors (Bridget Martell and Carole Nuechterlein), ratification of Ernst \u0026 Young LLP as auditor, approval of an amendment to the 2020 Employee Stock Purchase Plan (ESPP) reserving an additional 500,000 shares and eliminating the evergreen provision, advisory vote on named executive officer compensation, and advisory vote on the frequency of future compensation votes. The filing discloses the tabulated voting results for each proposal.","company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","filing_date":"2026-06-26","form":"8-K","submitted_at":null,"items":[{"id":11565,"accession_number":"0001193125-26-285426","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the Company's 2020 Employee Stock Purchase Plan (ESPP), which is a compensatory arrangement for employees. The amendment reserves an additional 500,000 shares for issuance and eliminates the evergreen provision, materially affecting the equity compensation structure available to employees. This falls squarely within exec_compensation as a compensation plan amendment requiring shareholder approval.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:04:54.388923+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11566,"accession_number":"0001193125-26-285426","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the tabulated results of an Annual Meeting of stockholders covering five proposals: election of two Class III directors (Bridget Martell and Carole Nuechterlein), ratification of Ernst \u0026 Young LLP as auditor, approval of an ESPP amendment, advisory vote on named executive officer compensation, and advisory vote on the frequency of future compensation votes. The filing explicitly states voting results with votes for, against, abstentions, and broker non-votes for each proposal, which is the core content of a shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:04:54.388923+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11565,"accession_number":"0001193125-26-285426","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the Company's 2020 Employee Stock Purchase Plan (ESPP), which is a compensatory arrangement for employees. The amendment reserves an additional 500,000 shares for issuance and eliminates the evergreen provision, materially affecting the equity compensation structure available to employees. This falls squarely within exec_compensation as a compensation plan amendment requiring shareholder approval.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:04:54.388923+00:00","company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","filing_date":"2026-06-26"},{"id":11566,"accession_number":"0001193125-26-285426","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the tabulated results of an Annual Meeting of stockholders covering five proposals: election of two Class III directors (Bridget Martell and Carole Nuechterlein), ratification of Ernst \u0026 Young LLP as auditor, approval of an ESPP amendment, advisory vote on named executive officer compensation, and advisory vote on the frequency of future compensation votes. The filing explicitly states voting results with votes for, against, abstentions, and broker non-votes for each proposal, which is the core content of a shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:04:54.388923+00:00","company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","filing_date":"2026-06-26"}]}